Finance

Lists
Why is PASG up 23.31%?
Dive Deeper
PASG:NASDAQ
Passage Bio Inc
$4.55
+23.31%
(+0.86) 1D
$4.23
-7.03% (-0.32)
After hours
Closed: Oct 12, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PASG...
Open
$3.61
High
$4.55
Low
$3.60
Mkt. cap
14.64M
Avg. vol.
24.30K
Volume
76.40K
52-wk high
$20.00
52-wk low
$3.30
EPS
-$11.32
Beta
1.40
Shares outstanding
3.21M
No. of employees
24
Open
$3.61
High
$4.55
Low
$3.60
Mkt. cap
14.64M
Avg. vol.
24.30K
Volume
76.40K
52-wk high
$20.00
52-wk low
$3.30
EPS
-$11.32
Beta
1.40
Shares outstanding
3.21M
No. of employees
24
News stories
From web sources and news partners
About Passage Bio Inc
CEO-
Employees24
Founded2017
HeadquartersPhiladelphia, Pennsylvania, United States
SectorBiotechnology
Websitepassagebio.com
Analyst ratings
Based on 1 analyst giving stock ratings to PASG in the past 3 months
Hold
Buy
0
Hold
1
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for PASG in the last 3 months
Highest
Current $4.55
(-100.00%)
Average
(-100.00%)
Lowest
(-100.00%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brendan Smith
TD Cowen
Hold
Maintained
-
-
08/10/2026
Debjit Chattopadhyay
Guggenheim
Hold
Downgraded
-
-
06/10/2026
Yaron Werber
TD Cowen
Hold
Downgraded
-
-
04/21/2026
Jay Olson
Oppenheimer
Buy
Reiterated
$15.00
+229.7%
04/21/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$23.00
+405.5%
04/21/2026
Janani Sundararajan
Chardan Capital
Hold
Downgraded
$7.00
+53.8%
04/20/2026
Yun Zhong
Wedbush
Hold
Downgraded
$8.00
+75.8%
04/21/2026
Elemer Piros
Lucid Capital
Hold
Downgraded
$9.00
+97.8%
04/20/2026
Last report
Aug 10, 2026
Fiscal period
Q2 2026
-$2.44 / -$2.84
+13.93%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
4.31M
5.42M
4.09M
3.34M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.35M
4.92M
4.79M
6.87M
Operating expense
8.66M
10.34M
8.88M
10.22M
Total operating expenses
8.66M
10.34M
8.88M
10.22M
Operating income
-8.66M
-10.34M
-8.88M
-10.22M
Other non operating income
406.00K
365.00K
388.00K
151.00K
EBT including unusual items
-7.75M
-12.98M
-7.56M
-7.82M
EBT excluding unusual items
-7.75M
-9.48M
-8.19M
-9.76M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-7.75M
-12.98M
-7.56M
-7.82M
Net profit margin
-
-
-
-
Earnings per share
-2.44
-4.09
-2.36
-2.44
Interest and investment income
500.00K
500.00K
300.00K
300.00K
Interest expense
-
-
-
-
Net interest expenses
500.00K
500.00K
300.00K
300.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-8.47M
-10.16M
-8.75M
-10.19M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps